PMC2 A BAYESIAN ADAPTIVE DESIGN FOR EVALUATION OF THE GAP BETWEEN EFFICACY AND ERROR-ADJUSTED EFFECTIVENESS  by Moriwaki, K et al.
Centricity are compared with national US data (NHANES,
NHIS, Kaiser Family Foundation and Census) including demo-
graphics and two common diseases, hypertension and diabetes.
Data from 2004 and 2005 are used for all comparisons. EMR
data is included for all patients with activity in 2005. ICD-9
codes were used to identify patients. FBG levels were used in
NHANES patients for diabetes. RESULTS: In total, 3,127,682
EMR patients were available; 2,644,181 of these were 18 and
older. EMR population was older than the general US popula-
tion. A percentage of EMR patients was lower in <18 and 18–44,
and higher in 45–64, 65–74, and 75+. EMR patients had pre-
dominantly commercial insurance (73.0%) and those with Med-
icaid were lower and Medicare higher than the US population.
Racial distribution was similar with EMR having a lower per-
centage of white patients (78.8%, 81.0%) and a higher percent-
age of black patients (13.5%, 12.7%). EMR patients were
overrepresented in the Northeast and Midwest and underrepre-
sented in the West and South and were predominantly female
(59.9%). A total of 683,936 hypertensive EMR patients were
identiﬁed (258.7/1000) as compared with 248.7/1000 (NHIS).
Prevalence of hypertension in EMR patients was higher in
males than females (286.6/1000 vs. 240.0/1000). Adult diabetic
patients were overrepresented in the EMR with 97.8/1000 vs
71.7/1000 (NHIS) and 58.6/1000 (NHANES (FPG > 125 mg/
dl)). CONCLUSION: EMR patients are older than the US popu-
lation and more likely to be female. Prevalence values were
similar for hypertension and higher in EMR patients for diabetes.
This may reﬂect the fact that the EMR is used primarily in
ambulatory primary care practices. EMR data is generally rep-
resentative of the US population but differences may exist
depending on the disease and population of interest.
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OBJECTIVES: The gap between “efﬁcacy” in clinical trials and
“effectiveness” in real practice due to patient selection, non-
compliance and treatment patterns has been broadly recognized
among health-care decision makers. However little attention has
been paid for statistical errors accompanied in clinical trials,
which may cause the gap. The purpose of this study is to develop
a new analytical framework to estimate the degree of the gap
caused by statistical errors. METHODS: The expected cost-
effectiveness ratio (QP) in the real world was formulated in terms
of a vector by using a decision analytic approach assuming an
evidence-based treatment choice from two treatment options: a
new treatment (TA) and a conventional treatment (TB). The
value of QP varies depending on the parameters such as cost-
effectiveness evidence of TA and TB, type  and type  errors,
and a Bayesian prior probability that TA is better than TB. The
prior probability is usually estimated by the following two steps:
1) Bayesian inference based on binomial modeling, and 2)
Normal approximation of the binomial modeling with the log
odds ratio. Then the derived prior probability was applied for
our formula to estimate the gap, called “gap formula”, by using
a hypothetical dataset. In addition, a Monte Carlo simulation
was performed as probabilistic sensitivity analysis. RESULTS:
Adaptive estimations of Bayes provided ﬂexible evaluation for
the gap formula between real world and clinical trials. The result
of the Monte Carlo simulations quantitatively illustrated with
distributions how much the QP could be deviated, mainly
depending on the type  error, from the ideal average cost-
effectiveness ratio. CONCLUSION: The series of methods we
developed can be applied in adaptive design for trial-based cost-
effectiveness analyses such as sample-size calculation considering
the inﬂuence of statistical errors.
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OBJECTIVES: In probabilistic sensitivity analysis of a cost-
effectiveness (CE) study, the unknown parameters, like transition
probabilities, are considered random variables. A crucial ques-
tion is what probabilistic distribution is suitable as synthesizing
the available information (mainly data from clinical trials) about
these parameters. In this context, it has been recognized the
important role of the Bayesian methodology, under which, the
parameters are of random nature.
Despite the great appealing of the Bayesian approach to proba-
bilistic sensitivity analysis, the “lack of objectivity” has been
frequently argued as the main issue precluding the adoption of
Bayesian techniques. This legitime concern has inspired the
development of formal objective priors over the last decades.
These priors are obtained as the result of mathematical formal
rules applied to the models at hand and lead to Bayesian analyses
inﬂuenced only by the data at hand. Formal objective priors have
a number of appealing properties, including excellent frequentist
behaviour.
We explore, in the context of CE analyses, how formal
objective Bayesian methods can be implemented. Speciﬁcally,
we consider two problems that frequently appear in the CE
literature: survival analysis and meta-analysis. We describe in
detail the numerical methods that needs to be used to obtain the
results.
The methodology is fully illustrated using two CE analysis
published in the literature. We compare our results with those
obtained with other approaches to probabilistic sensitivity analy-
sis. We conclude that the differences, when compared with other
approaches, can be quite quite marked, specially when the
number of patients enrolled in the simulated cohort under study
is large.
PMC4
PROBABILISTIC SENSITIVITY ANALYSES IN HEALTH
ECONOMIC MODELING STUDIES:A QUALITY ASSESSMENT
Getsios D1, Ishak KJ2, Finnegan S3, Caro JJ3
1United BioSource Corporation, Halifax, NS, Canada, 2United
BioSource Corporation, Montreal, QC, Canada, 3United BioSource
Corporation, Concord, MA, USA
OBJECTIVES: Probabilistic sensitivity analysis (PSA) of eco-
nomic evaluations has become more important because decision
makers want to know how uncertain results are. We evaluated
the consistency of PSA methods and how well they adhered
to published recommendations. METHODS: Publications of
methodological guidelines on the conduct of PSA were re-
viewed by three researchers, and a consensus set of criteria
for assessing PSAs were developed. English language health
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